The ROE as of December 2024 (TTM) for Lyell Immunopharma, Inc. (LYEL) is -34.64%

According to Lyell Immunopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -34.64%. This represents a change of 300.19% compared to the average of -8.66% of the last 4 quarters.

Lyell Immunopharma, Inc. (LYEL) Historical ROE (quarterly & annually)

How has LYEL ROE performed in the past?

The mean historical ROE of Lyell Immunopharma, Inc. over the last ten years is -24.89%. The current -34.64% ROE has changed 39.19% with respect to the historical average. Over the past ten years (40 quarters), LYEL's ROE was at its highest in in the December 2022 quarter at 0.29%. The ROE was at its lowest in in the March 2023 quarter at -16.92%.

Lyell Immunopharma, Inc. (LYEL) ROE by Quarter and Year

Discovering the peaks and valleys of Lyell Immunopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lyell Immunopharma, Inc. (LYEL) Average ROE

How has LYEL ROE performed in the past?

The current ROE of Lyell Immunopharma, Inc. (LYEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Lyell Immunopharma, Inc. (LYEL) ROE vs. Peers

How is LYEL’s ROE compared to its peers?

Lyell Immunopharma, Inc.’s ROE is greater than Cullinan Oncology, Inc. (-26.54%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Revolution Medicines, Inc. (-33.67%), greater than Nkarta, Inc. (-27.13%), greater than Generation Bio Co. (-104.85%), greater than Sana Biotechnology, Inc. (-94.47%), greater than Nuvation Bio Inc. (-108.68%), greater than Century Therapeutics, Inc. (-66.58%), greater than Shattuck Labs, Inc. (-61.92%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), less than Inhibrx Biosciences, Inc. (1.45%), greater than Merus N.V. (-45.38%), greater than Kronos Bio, Inc. (-64.55%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Mineralys Therapeutics, Inc. (-55.92%),

Build a custom stock screener for Lyell Immunopharma, Inc. (LYEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyell Immunopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lyell Immunopharma, Inc. (LYEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lyell Immunopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.